Clinical Trial Update: Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia [Phase 2]

View source ↗

Summary

Phase 2 trial updates short-term outcomes of N-Carbamylglutamate for acute hyperammonemia in several metabolic disorders; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carbamoyl-phosphate Synthase Deficiency Disease
• Methylmalonic Acidemia
• Ornithine Carbamoyltransferase Deficiency
• Propionic Acidemia

Drugs mentioned

• N-Carbamylglutamate (N-carbamylglutamate)

Snippet

Sponsor: Mendel Tuchman | Conditions: Propionic Acidemia, Type I and/or Type II, Methylmalonic Acidemia | Phase 2 | Status: COMPLETED | Results posted: 2021-02-15